caa a22 4500 467934576 CHVBK 20180406152953.0 cr unu---uuuuu 170328e20060201xx s 000 0 eng 10.1007/s00408-005-2558-2 doi (NATIONALLICENCE)springer-10.1007/s00408-005-2558-2 Role of Soluble Interleukin-2 Receptor Levels in Patients with Latent Tuberculosis [Elektronische Daten] [David Shitrit, Gabriel Izbicki, Ariella Shitrit, Meir Raz, Jaquline Sulkes, Mordechai Kramer] Serum soluble interleukin-2 receptor (sIL-2R) serves as a marker of disease activity in patients with tuberculosis (TB). However, little is known about its role in latent TB. The aim of this study was to assess the levels of sIL-2R in patients with latent TB and correlate them with the purified protein derivate (PPD) test results. Patients with a diagnosis of latent TB were divided into three subgroups by induration size: <10 mm, 10-20 mm, >20 mm. Blood was collected for sIL-2R assay. Findings were compared to a healthy control group. The study group consisted of 44 patients (68% male) of mean ( ± SD) age 20 ± 10 years, and the control group consisted of 41 subjects (42% male) aged 31 ± 11 years. Comparison of the two groups yielded a significantly higher serum sIL-2R level in the patients (450 ± 224 U/ml vs. 374 ± 30 U/ml, p = 0.03). Mean sIL-2R levels were significantly correlated with the presence of latent TB (p = 0.03), and with purified protein derivative (PPD) subgroups: 387 ± 177 U/ml for induration size <10 mm, NS; 450 ± 238 U/ml for 10-20 mm, p = 0.04, and 605 ± 235 U/ml for >20 mm, p < 0.0001. sIL-2R assay may serve as an additional tool to estimate the extent of the immune response in patients with latent TB. Springer Science+Business Media, Inc., 2006 Tuberculin skin test nationallicence Soluble interleukin-2 receptor nationallicence Latent tuberculosis infection nationallicence Shitrit David Pulmonary Institute, Beilinson Campus, Rabin Medical Center, and Sackler School of Medicine, Tel Aviv University, 49100, Tel Aviv, Petah Tiqwa, Israel aut Izbicki Gabriel Pulmonary Institute, Beilinson Campus, Rabin Medical Center, and Sackler School of Medicine, Tel Aviv University, 49100, Tel Aviv, Petah Tiqwa, Israel aut Shitrit Ariella Department of Internal Medicine, Shaare-Zedek Medical Center, Jerusalem, Israel aut Raz Meir Macabbi Medical Service, Tuberculosis Center, Rehovot, Israel aut Sulkes Jaquline Epidemiology Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel aut Kramer Mordechai Pulmonary Institute, Beilinson Campus, Rabin Medical Center, and Sackler School of Medicine, Tel Aviv University, 49100, Tel Aviv, Petah Tiqwa, Israel aut Lung Springer-Verlag; www.springer-ny.com 184/1(2006-02-01), 21-24 0341-2040 184:1<21 2006 184 408 https://doi.org/10.1007/s00408-005-2558-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00408-005-2558-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Shitrit David Pulmonary Institute, Beilinson Campus, Rabin Medical Center, and Sackler School of Medicine, Tel Aviv University, 49100, Tel Aviv, Petah Tiqwa, Israel aut NATIONALLICENCE 700 1- Izbicki Gabriel Pulmonary Institute, Beilinson Campus, Rabin Medical Center, and Sackler School of Medicine, Tel Aviv University, 49100, Tel Aviv, Petah Tiqwa, Israel aut NATIONALLICENCE 700 1- Shitrit Ariella Department of Internal Medicine, Shaare-Zedek Medical Center, Jerusalem, Israel aut NATIONALLICENCE 700 1- Raz Meir Macabbi Medical Service, Tuberculosis Center, Rehovot, Israel aut NATIONALLICENCE 700 1- Sulkes Jaquline Epidemiology Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel aut NATIONALLICENCE 700 1- Kramer Mordechai Pulmonary Institute, Beilinson Campus, Rabin Medical Center, and Sackler School of Medicine, Tel Aviv University, 49100, Tel Aviv, Petah Tiqwa, Israel aut NATIONALLICENCE 773 0- Lung Springer-Verlag; www.springer-ny.com 184/1(2006-02-01), 21-24 0341-2040 184:1<21 2006 184 408 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer